The association of dimethylarginine dimethylaminohydrolase 1 gene polymorphism with type 2 diabetes: A cohort study

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Lu, Tse Min ^a,b   Lin, Shing Jong ^a,b   Lin, Ming Wei ^a,b   Hsu, Chiao Po ^a,b   Chung, Ming Yi ^a,b  

^a TAIPEI VETERANS GENERAL HOSPITAL   (Taiwan)

^b NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

DIMETHYLARGININASE; GLUCOSE; N(G),N(G) DIMETHYLARGININE; AMIDASE; ARGININE; BIOLOGICAL MARKER; DRUG DERIVATIVE; INSULIN; N,N DIMETHYLARGININE; N,N-DIMETHYLARGININE;

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; FOLLOW UP; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GLUCOSE BLOOD LEVEL; HAPLOTYPE; HEART INFARCTION; HOMOZYGOSITY; HUMAN; INSULIN RESISTANCE; INSULIN SENSITIVITY; MAJOR CLINICAL STUDY; MALE; MORTALITY; NON INSULIN DEPENDENT DIABETES MELLITUS; SINGLE NUCLEOTIDE POLYMORPHISM; STROKE; ANALYSIS OF VARIANCE; ANGIOCARDIOGRAPHY; BLOOD; CASE CONTROL STUDY; CHI SQUARE DISTRIBUTION; ENZYMOLOGY; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENETICS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PHENOTYPE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RADIOGRAPHY; RISK; RISK ASSESSMENT; RISK FACTOR; STATISTICAL MODEL; TAIWAN;

AGED; AMIDOHYDROLASES; ANALYSIS OF VARIANCE; ARGININE; BIOLOGICAL MARKERS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COHORT STUDIES; CORONARY ANGIOGRAPHY; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; HAPLOTYPES; HUMANS; INSULIN; INSULIN RESISTANCE; KAPLAN-MEIER ESTIMATE; LINEAR MODELS; LINKAGE DISEQUILIBRIUM; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PHENOTYPE; POLYMORPHISM, GENETIC; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TAIWAN;

EID: 79651475617     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-16     Document Type: Article

References (42)

1. Schalkwijk CG, Stehouwer CD. Vascular complications in diabetes mellitus: the role of endothelial dysfunction. Clin Sci 2005, 109:143-159. 10.1042/CS20050025, 16033329.
2. Steinberg HO, Brechtel G, Johnson A, Fineberg N, Baron AD. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent. A novel action of insulin to increase nitric oxide release. J Clin Invest 1994, 94:1172-1179. 10.1172/JCI117433, 295191, 8083357.
3. Vincent MA, Clerk LH, Lindner JR, Klinbanov AL, Clark MG, Ratiggan S, Barrett EJ. Microvascular recruitment is an early insulin effect that regulates skeletal muscle glucose uptake in vivo. Diabetes 2004, 53:1418-1423. 10.2337/diabetes.53.6.1418, 15161743.
4. Kakimoto Y, Akazawa S. Isolation and identification of NG, NG- and NG, N'G dimethyl-arginine, Ne-mono-, di-, and trimethyllysine, glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J Biol Chem 1970, 245:5751-5758.
5. Vallance P, Leone A, Calver A, Collier J, Moncada S. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet 1992, 339:572-575. 10.1016/0140-6736(92)90865-Z, 1347093.
6. Leiper J, Vallance P. Biological significance of endogenous methylarginines that inhibit nitric oxide synthases. Cardiovasc Res 1999, 43:542-548. 10.1016/S0008-6363(99)00162-5, 10690326.
7. Böger RH, Bode-Böger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol 2000, 36:2287-2295.
8. Stühlinger MC, Abbasi F, Chu JW, Lamendola C, McLaughlin TL, Cooke JP, Reaven GM, Tsao PS. Relationship between insulin resistance and an endogenous nitric oxide synthase inhibitor. JAMA 2002, 287:1420-1426.
9. Abbasi F, Asagmi T, Cooke JP, Lamendola C, McLaughlin T, Reaven GM, Stühlinger M, Tsao PS. Plasma concentrations of asymmetric dimethylarginine are increased in patients with type 2 diabetes mellitus. Am J Cardiol 2001, 88:1201-1203. 10.1016/S0002-9149(01)02063-X, 11703973.
10. Altinova AE, Arslan M, Sepici-Dincel A, Akturk M, Altan N, Toruner FB. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab 2007, 92:1881-1885. 10.1210/jc.2006-2643, 17311854.
11. Krzyzanowska K, Mittermayer F, Krugluger W, Schnack C, Hofer M, Wolzt M, Schernthaner G. Asymmetric dimethylarginine is associated with macrovascular disease and total homocysteine in patients with type 2 diabetes. Atherosclerosis 2006, 189:236-240. 10.1016/j.atherosclerosis.2005.12.007, 16414052.
12. Abhary S, Kasmeridis N, Burdon KP, Kuot A, Whiting MJ, Yew WP, Petrovsky N, Craig JE. Diabetic retinopathy is associated with elevated serum asymmetric and symmetric dimethylarginines. Diabetes Care 2009, 32:2084-2086. 10.2337/dc09-0816, 2768206, 19675197.
13. Krzyzanowska K, Wolzt M, Mittermayer F, Schernthaner G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 2007, 30:1834-1839. 10.2337/dc07-0019, 17456842.
14. Lajer M, Teerlink T, Tarnow L, Parving H, Jorsal A, Rossing P. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care 2008, 31:747-752. 10.2337/dc07-1762, 18162497.
15. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and actively metabolized by dimetylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003, 23:1455-1459. 10.1161/01.ATV.0000081742.92006.59, 12805079.
16. Leiper JM, Santa Maria JS, Chubb ARJ, MacAllister RJ, Charles IG, Whitley G, Vallance P. Identification of two human dimethylarginine dimethylaminohydrolases with distinct distribution and homology with microbial arginine deaminases. Biochem J 1999, 343:209-214. 10.1042/0264-6021:3430209, 1220543, 10493931.
17. Sydow K, Mondon CE, Schrader J, Konishi H, Cooke JP. Dimethylarginine dimethylaminohydrolase overexpression enhances insulin sensitivity. Arterioscler Thromb Vasc Biol 2008, 28:692-697. 10.1161/ATVBAHA.108.162073, 18239148.
18. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus: Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003, 26:3160-3167. 10.2337/diacare.26.11.3160, 14578255.
19. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. JAMA 2003, 289:2560-2572. 10.1001/jama.289.19.2560, 12748199.
20. Lu TM, Ding YA, Lin SJ, Lee WS, Tai HC. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J 2003, 24:1912-1919. 10.1016/j.ehj.2003.08.013, 14585249.
21. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and β-cell function from fasting glucose and insulin concentration in man. Diabetologia 1985, 28:412-419. 10.1007/BF00280883, 3899825.
22. Ma YC, Zuo L, Chen JH, Luo Q, Yu XQ, Li Y, Xu JS, Huang SM, Wang LN, Huang W, Wang M, Xu GB, Wang HY. Modified glomerular filtration rate estimating equation for Chinese patients with chronic kidney disease. J Am Soc Nephrol 2006, 17:2937-2944. 10.1681/ASN.2006040368, 16988059.
23. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D. The structure of haplotype blocks in the human genome. Science 2002, 296:2225-2229. 10.1126/science.1069424, 12029063.
24. Hamed S, Brenner B, Aharon A, Daoud D, Roguin A. Nitric oxide and superoxide dismutase modulate endothelial progenitor cell function in type 2 diabetes mellitus. Cardiovasc Diabetol 2009, 8:56. 10.1186/1475-2840-8-56, 2773759, 19878539.
25. Thum T, Tsikas D, Stein S, Schultheiss M, Eigenthaler M, Anker SD, Poole-Wilson PA, Ertl G, Bauersachs J. Suppression of endothelial progenitor cells in human coronary artery disease by the endogenous nitric oxide synthase inhibitor asymmetric dimethylarginine. J Am Coll Cardiol 2005, 46:1693-1701. 10.1016/j.jacc.2005.04.066, 16256870.
26. Lin KY, Ito A, Asagami T, Tsao PS, Adimoolam S, Kimoto M, Tsuji H, Reaven GM, Cooke JP. Impaired nitric oxide synthase pathway in diabetes mellitus: role of asymmetric dimethylarginine and dimethylarginine dimethylaminohydrolase. Circulation 2002, 106:987-992. 10.1161/01.CIR.0000027109.14149.67, 12186805.
27. Leiper J, Nandi M, Torondel B, Murray-Rust J, Malaki M, O'Hara B, Rossiter S, Anthony S, Madhani M, Selwood D, Smith C, Wojciak-Stothard B, Rudiger A, Stidwill R, McDonald NQ, Vallance P. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007, 13:198-203. 10.1038/nm1543, 17273169.
28. Hu X, Xu X, Zhu G, Atzler D, Kimoto M, Chen J, Schwedhelm E, Lüneburg N, Böger RH, Zhang P, Chen Y. Vascular endothelium specific dimethylarginine dimethylaminohydrolas-1 deficient mice reveal vascular endothelium play an important role in removing asymmetric dimethylarginine. Circulation 2009, 120:2222-2229. 10.1161/CIRCULATIONAHA.108.819912, 2804399, 19917889.
29. Dayoub H, Achan V, Adimoolam S, Jacobi J, Stuehlinger MC, Wang BY, Tsao PS, Kimoto M, Vallance P, Patterson AJ, Cooke JP. Dimethylarginine dimethylaminohydrolase regulates nitric oxide syntheses: genetic and physiological evidence. Circulation 2003, 108:3042-3047. 10.1161/01.CIR.0000101924.04515.2E, 14638548.
30. Wolf C, Lorenzen JM, Stein S, Tsikas D, Störk S, Weidemann F, Ertl G, Anker SD, Bauersachs J, Thum T. Urinary asymmetric dimethylarginine (ADMA) is a predictor of mortality risk in patients with coronary artery disease. In J Cardiol 2010,
31. Abhary S, Burdon KP, Kout A, Javadiyan S, Whiting MJ, Kasmeridis N, Petrovsky N, Craig JE. Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes. PLos ONE 2010, 5:e9462. 10.1371/journal.pone.0009462, 2830883, 20209122.
32. Ding H, Wu B, Wang H, Lu Z, Yan J, Wang X, Shaffer JR, Hui R, Wang DW. A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease. Circ Res 2010, 106:1145-1152. 10.1161/CIRCRESAHA.109.215616, 20167924.
33. Caplin B, Nitsch D, Gill H, Hoefield R, Blackwell, MacKenzie D, Cooper JA, Middleton RJ, Talmud PJ, Veitch P, Norman J, Wheeler DC, Leiper JM. Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms. Kidney Int 2010, 77:459-467. 10.1038/ki.2009.463, 20010544.
34. Ravani P, Tripepi G, Malberti F, Testa S, Mallamaci F, Zoccali C. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol 2005, 16:2449-2455. 10.1681/ASN.2005010076, 15944335.
35. Meinitzer A, Seelhorst U, Wellnitz B, Halwachs-Baumann G, Boehm B, Winkelmann BR, März W. Asymmetrical dimethylarginine independently predicts total cardiovascular mortality in individuals with angiographic coronary artery disease (The Ludwigshafen risk and cardiovascular health study). Clin Chem 2007, 53:273-283. 10.1373/clinchem.2006.076711, 17185364.
36. Böger RH, Sullivan LM, Schwedhelm E, Wang TJ, Maas R, Benjamin EJ, Schulze F, Xanthakis V, Benndorf RA, Vasan SR. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 2009, 119:1592-1600. 2742491, 19289633.
37. Sibal L, Agarwal SC, Schwedhelm E, Lüneburg N, Böger RH, Home PD. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with type I diabetes without macrovascular disease or macroalbuminuria. Cardiovasc Diabetol 2009, 8:27. 10.1186/1475-2840-8-27, 2698883, 19486510.
38. Ceriello A, Quagliaro L, Catone B, Pascon R, Piazzola M, Bais B, Marra G, Tonutti L, Taboga C, Motz E. Role of hyperglycemia in nitrotyrosine postprandial generation. Diabetes Care 2002, 25:1439-1443. 10.2337/diacare.25.8.1439, 12145247.
39. Dixon LJ, Hughes SM, Roodney K, Madden A, Devine A, Leahey W, Henry W, Johnston GD, McVeigh GE. Increased superoxide production in hypertensive patients with diabetes mellitus: role of nitric oxide synthase. Am J Hypertens 2005, 18:839-843. 10.1016/j.amjhyper.2005.01.004, 15925745.
40. Anderssohn M, Schwehelm E, Lüneburg N, Vasan SR, Böger RH. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diabetes Vasc Dis Res 2010, 7:105-118.
41. Lu TM, Ding YA, Leu HB, Yin WH, Sheu WH, Chu KM. Effect of rosuvastatin on plasma levels of asymmetric dimethylarginine in patients with hypercholesterolemia. Am J Cardiol 2004, 94:157-161. 10.1016/j.amjcard.2004.03.052, 15246890.
42. Delles C, Schneider MP, John S, Gekle M, Schmieder RE. Angiotensin converting enzyme inhibition and angiotensin II AT1-receptor blockade reduce the levels of asymmetrical N(G), N(G)-dimethylarginine in human essential hypertension. Am J Hypertens 2002, 15:590-593. 10.1016/S0895-7061(02)02278-1, 12118904.